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ABSTRACT 
Metabolic syndrome (MetS) is characterized by a cluster of disorders like obesity, insulin resistance, glucose intolerance, hypertension and 
dyslipidemia. All these disorders are responsible for the development of secondary morbid and co-morbid conditions. The current review focuses 
on the molecular pathogenesis of secondary late complications associated with metabolic syndrome including cognitive impairment, depressive 
disorder, neuropathy, arthritis and colorectal cancer.  
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INTRODUCTION 
Metabolic syndrome (MetS) is a multiple factorial condition that 
draws a parallel to various risks such as dyslipidemia, hypertension, 
and hyperglycemia. As per the new International Diabetes 
Federation (IDF), for a person to be defined as having metabolic 
syndrome they must have central obesity along with any two of the 
following four factors: Raised triglycerides (≥ 150 mg/dL), reduced 
HDL cholesterol (<40 mg/dL in males and<50 mg/dL in females), 
raised blood pressure (systolic BP ≥ 130 or diastolic BP ≥ 85 mm 
Hg) and raised fasting plasma glucose (FPG ≥ 100 mg/dL) [1]. 
According to previous reports about 20 to 30 % of world population 
is currently suffering from metabolic syndrome [2]. Mets have been 
associated with increase in age and BMI [3]. In MetS, there is a 
tendency to develop central obesity associated with an increase in 
circulatory free fatty acids [4]. This eventually leads to increase in 
blood pressure, insulin-resistance and hyperlipidemia [5]. Insulin 
resistance is often projected to be the major cause of Mets; however 
there are other factors like genetic variations in breaking down 
lipids in blood and age, which may contribute to its development [6]. 
Metabolic syndrome may give rise to a number of secondary 
complications which primarily include atherosclerosis and other 
cardiovascular disorders (reviewed in details by Reaven G 2002) [6]. 
Dementia, neuropathy, arthritis and colorectal cancer. The present 
review focuses on the mechanisms associated with the pathogenesis 
of late complications of MetS like cognitive impairment, depression, 
neuropathy, arthritis and colorectal cancer. 
Cognition impairment and metabolic syndrome 
Evidence suggests that MetS and associated factors such as visceral 
obesity, elevated triglycerides, elevated fasting blood glucose, high 
blood pressure and decreased HDL all have detrimental effects on 
cognition [7, 8]. Biological toxicity occurs with increase in plasma 
glucose levels causing protein glycation, alteration of redox potential 
and generation of reactive oxygen species [9]. The ensuing oxidative 
stress may lead to vascular damage. This microvascular dysfunction 
may prove to be detrimental to hippocampal neurons leading to 
cognitive deficit [10] Release of excess glucocorticoides may 
augment natural fat and cause insulin resistance [11, 12]. Increased 
cortisol level due to stress has been correlated with signs of MetS 
[13] Cortisol may also reduce the amount of insulin transported 
across the blood–brain barrier [14] Glycemic control affects 
cognitive performance that relies mostly on hippocampal neurons 
[15] Animal studies have shown that the transportation of glucose to 
the hippocampal neurons and glia is inhibited by glucocorticoids 
[16] This may be due to excessive localization of cortisol and insulin 
receptors in the hippocampal regions of the brain [7, 17]. Some 
studies have also proposed the role of cerebral white matter lesions 
in the development of stroke, cognitive impairment and dementia 
[18]. Large white matter hyper-intensities have been associated 
with disturbed cerebral perfusion in human volunteers. These 
studies have also shown cerebral metabolic abnormalities in white 
matter atrophy. Marred cerebral white matter is intertwined with 
attenuated cerebrovascular hemodynamics [19]. Elevated blood 
pressure, dyslipidemia and elevated fasting glucose levels associated 
with MetS have been implicated in subcortical white matter lesions, 
peri ventricular hyperintensities and silent ischemic brain lesions 
[20]. All of the above factors have been implicated in the 
pathogenesis of MetS associated cognitive deficits [7]. 
Metabolic syndrome associated neuropathy 
Prevalence of impaired glucose tolerance has been associated with 
40–50% of idiopathic neuropathy patients [21]. Mechanisms of 
injury include fatty deposition in nerves, extracellular protein 
glycation, mitochondrial dysfunction, and oxidative stress [22, 23] 
Hyperglycaemia and hyperlipidemia associated with metabolic 
syndrome may cause cellular damage with production of reactive 
oxygen species leading to mitochondrial dysfunction and endo 
plasmic reticulum (ER) stress [24,25]. These changes not only lead 
to direct neuronal injury but also promote insulin-resistance 
mediated by excess nutrient, initiating tissue inflammation, which in 
turn may exacerbate insulin resistance.  
In MetS .This is in C-reactive protein and pro-inflammatory state is 
well documented due to recruitment of leukocyte by chemokines via 
Jun N-terminal kinases (JNK) and inhibitor of nuclear factor Kb 
kinase (IKK) causing tissue damage. JNK and IKKb also mediate 
further production of inflammatory and tissue-damaging signals by 
activation of nuclear factor kappa B (NFkB) [26, 27]. There is a 
strong correlation between NFKB activation and release of pro-
inflammatory cytokines like Interleukin-6 (IL-6) and Tumor necrosis 
factor alpha (TNF-α) leading to neuronal dysfunction in diabetic 
neuropathy. Advanced glycation end products (AGEs) may also 
stimulate NFKB thus contributing to the disease process [28].  
Metabolic syndrome associated depressive disorders 
MetS have been associated with depressive disorders, while others 
have shown women with depressive disorders are more likely to 
develop metabolic syndrome [29, 30]. Hyperactivity of the 
hypothalamic-pituitary-adrenal (HPA) axis which is vital to the 
stress response has major implications in depressive disorders. 
Promotion of glucose uptake by insulin is hampered by excessive 
rise in glucocorticoids leading to deposition of body fat. Individuals 
suffering from mood disorders due to cortisol dys regulation often 
show increased frequency of MetS [31]. Activation of immuno-
inflammatory networks by alteration in insulin sensitivity may affect 
the neuronal or glial cells by oxidative stress mechanisms. The 
metabolic syndrome and insulin resistance are also strongly linked 
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with elevated inflammatory markers [27, 32]. Adipose tissue during 
obesity and metabolic syndrome has been associated with the 
secretion of pro-inflammatory cytokines such as TNF-α, resistin, IL-6 
[33, 34]. Activated pro-inflammatory cytokines induce “sickness 
behaviour”, a syndrome phenotypically similar to depressive 
disorders that include anorexia, sleep disturbance and decreased 
self care behaviour in rodents [35]. Depressive disorders have also 
been associated with increased cytokine levels in various clinical 
studies [36, 37]. Adipocytes are known to have receptors for 
Oestrogen, PPARγ, Insulin like growth factor, insulin and leptin and 
may release an array of secretary products like leptin and oestrogen 
which can be associated with depressive disorders [38]. Reduced 
oestrogen levels have long been associated with anxiety and 
depression especially in women [39]. Oestrogen receptor α (ER-α) 
also plays an important role in oestrogen mediated regulation of 
metabolism [35]. Suppression of ER-α expression in the 
hypothalamic nuclei of female mice and rats develop a phenotype 
characteristic of metabolic syndrome marked by obesity and 
impaired glucose tolerance [40].  
Arthritis and metabolic syndrome 
Metabolic syndrome and Insulin resistance and obisity have been 
independently associated with psoriatic arthritis, which is 
characterized by joint pain, stiffness and swelling, underlined by a 
systemic inflammatory state [41, 42]. There is increased evidence 
that chronic inflammation and immune dysregulation may 
contribute to accelerated atherogenesis and may play a major role in 
all stages of atherosclerosis (i.e., atherogenesis, atheroma 
progression, and the development of thrombosis) [43]. Studies 
suggest that patients with rheumatoid arthritis (RA) have 
accelerated atherosclerosis. Thus, inflammation associated with RA 
may contribute to increased risk for metabolic syndrome and 
coronary-artery disease [44]. Pro-inflammatory cytokines like IL-1β, 
TNF-α and C-reactive protein (CRP) have been shown to be up 
regulated in RA. While the healthy endothelium prevents adhesion 
of mononuclear cells, during inflammation they express adhesion 
molecules [selectins, vascular adhesion molecule (VCAM)-1, 
intercellular adhesion molecule (ICAM)-1]. Which promotes the 
adherence of monocytes to the endothelium, which is believed to be 
the earliest events in atherosclerogenesis [45]. Inflammatory 
cytokines like TNF-α may itself induce insulin resistance and 
suppression of glucose transporter (Glut)-4 expression by inhibiting 
insulin receptor autophoshorylation or by inducing serine 
phosphorylation of insulin receptor substrate (IRS)-1. Leptin 
produced by adipose tissues may also contribute to insulin 
resistance through phosphorylation of serine residues of IRS-1. The 
involvement of inflammatory cytokines in insulin resistance is 
mainly important for the following reasons. First, it correlates 
adipose tissue, a major source of inflammatory cytokines in patients 
with abdominal obesity with insulin resistance and MetS. Secondly, 
it provides a plausible explanation for the interplay between chronic 
inflammatory diseases like RA and MetS [46]. Thus although RA and 
MetS have often been observed to coexist and various plausible 
mechanisms may correlate them further studies need to be 
conducted to prove their association. 
Metabolic syndrome and colorectal cancer 
The role of insulin in the etiology of colorectal cancer is implicated 
by various observational and meta-analysis studies [47, 48]. 
Numerous epidemiological studies have shown a significant 
correlation between hyperinsulinemia and risk of colorectal cancers 
[49,50]. Mitogenic action of insulin via insulin receptors has been 
largely implicated in the association of MetS with colorectal cancer 
[51,52]. In MetS associate obesity, adipocytes have an important role 
in the pathogenesis of colorectal cancer. Adeponectin, the hormone 
secreted by adipocytes regulates not only glucose metabolism but 
also sensitizes peripheral tissue to insulin [53]. Clinical studies also 
demonstrate the association of visceral fat accumulation and 
decreased plasma adiponectin concentration in metabolic syndrome 
[54]. On the other side insulin resistance leading to reduction in 
adeponectine is the predominant feature associated with chronic 
hyperinsulinaemia. Insulin and IGF1 promote mitogenesis and 
inhibit apoptosis via caspase-mediated pathway in endothelial cells. 
This leads to tumorogenesis by the action of insulin receptors (IRs) 
and IGF1 receptor (IGF1R) [55-57]. IGF 1 may also upregulate the 
secretion of vascular endothelial growth factor (VEGF), leading to 
angiogenesis [58]. Adiponectin also inhibits the production of TNF-α 
by macrophages and its destructive action on endothelial cells 
stimulates angiogenesis [59]. Reduction in circulatory adiponectin 
levels has inherent ability to induce tumorogeneses mediated by 
TNF-α [60]. Insulin inhibits transcription of IGFBP-1, which 
increases circulating IGFs [61]. High levels of circulating IGF-I 
increase cellular proliferation and inhibit apoptosis, increasing the 
risk for colorectal cancer [62]. Thus in MetS, tumorigenic action of 
insulin, adeponectine and IGF, and inhibitory action of adeponectin 
on TNF-α in macrophages are the primary cause of colorectal cancer. 
Recent studies also show the role of HMGA1 gene, key player in 
cancer progression to be a key regulator for insulin receptor (INSR) 
gene. Polymorphism in the HMGA1 is associated with the risk of 
insulin-resistance during metabolic syndrome [63]. While defects in 
HMGA1 protein causes reduced level of INSR expression and 
increased susceptibility to hyperinsulinemic state [64, 65]. 
CONCLUSION 
Hyperlipidemia and hyperglycemia associated with MetS form the 
major basis for development of secondary complications. MetS 
induced oxidative stress may play important role in development of 
cognitive impairment, neuropathy and depressive disorders while 
its effect on cell proliferation, angiogenesis and apoptosis may 
contribute to the pathogenesis of colorectal cancer.  
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